{
    "ticker": "SABS",
    "name": "SAB Biotherapeutics, Inc.",
    "description": "SAB Biotherapeutics, Inc. is an innovative biotechnology company focused on developing a new class of immunotherapies based on its proprietary technology platform. Founded in 2014, SAB harnesses the power of the immune system to produce fully human polyclonal antibodies, which are critical for the treatment and prevention of various diseases. The company's lead product, SAB-185, is designed to treat and prevent infectious diseases, including COVID-19. By utilizing genetically engineered cattle that produce human antibodies, SAB aims to create therapies that are safe, effective, and scalable. With a commitment to addressing unmet medical needs, SAB Biotherapeutics is at the forefront of advancing immunotherapy solutions to improve patient outcomes in a variety of therapeutic areas, including infectious diseases, autoimmune disorders, and cancer. The company is dedicated to scientific excellence and collaborates with leading research institutions and pharmaceutical companies to expedite the development of its innovative therapies, ultimately striving to enhance global health and well-being.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Sioux Falls, South Dakota, USA",
    "founded": "2014",
    "website": "https://www.sabbiotherapeutics.com",
    "ceo": "E. Thomas McLain",
    "social_media": {
        "twitter": "https://twitter.com/SABBiotherapeutics",
        "linkedin": "https://www.linkedin.com/company/sab-biotherapeutics/"
    },
    "investor_relations": "https://www.sabbiotherapeutics.com/investors",
    "key_executives": [
        {
            "name": "E. Thomas McLain",
            "position": "CEO"
        },
        {
            "name": "Cathy L. Kearney",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "SAB-185"
            ]
        }
    ],
    "seo": {
        "meta_title": "SAB Biotherapeutics, Inc. | Innovative Immunotherapy Solutions",
        "meta_description": "Explore SAB Biotherapeutics, Inc., a leader in immunotherapy development. Learn about SAB's groundbreaking therapies and commitment to advancing global health.",
        "keywords": [
            "SAB Biotherapeutics",
            "Immunotherapy",
            "Biotechnology",
            "Polyclonal Antibodies",
            "SAB-185"
        ]
    },
    "faq": [
        {
            "question": "What is SAB Biotherapeutics known for?",
            "answer": "SAB Biotherapeutics is known for developing innovative immunotherapies based on fully human polyclonal antibodies."
        },
        {
            "question": "Who is the CEO of SAB Biotherapeutics?",
            "answer": "E. Thomas McLain is the CEO of SAB Biotherapeutics, Inc."
        },
        {
            "question": "Where is SAB Biotherapeutics headquartered?",
            "answer": "SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota, USA."
        },
        {
            "question": "What is SAB's lead product?",
            "answer": "SAB's lead product is SAB-185, designed for the treatment and prevention of infectious diseases, including COVID-19."
        },
        {
            "question": "When was SAB Biotherapeutics founded?",
            "answer": "SAB Biotherapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "NVAX",
        "PFE"
    ]
}